Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Amerikaanse aandelen  /  Innovus Pharmaceutic

Ontvang nu dagelijks onze kooptips!

word abonnee

Amerikaanse aandelen« Terug naar discussie overzicht

Innovus Pharmaceutic

19 Posts
| Omlaag ↓
  4. [verwijderd] 24 mei 2016 06:10
    SeeThruEquity Issues Update Note on Innovus Pharmaceuticals, Inc. (OTCQB: INNV) with a Price Target of $0.91
    ACCESSWIRE via CMTX - Mon May 23, 8:00AM CDT

    NEW YORK, NY / ACCESSWIRE / May 23, 2016 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on Innovus Pharmaceuticals, Inc. (OTCQB:INNV).

    The note is available here: INNV May 2016 Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

    Innovus Pharmaceuticals, Inc. (OTCBB: INNV, "Innovus") is an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter (OTC) medicine and consumer care products to improve men and women's health, respiratory disease and vitality. Innovus recently released 1Q16 results, which showed double-digit organic growth as well as controlled operating expenses. The company recently completed the acquisition of Beyond Human™, which has expanded its pipeline to include 13 commercialized products and three pipeline products, and has several upcoming key milestones on the horizon, including:

    Fluticare™: Innovus management expects to hear from the FDA regarding its ANDA for Fluticare™, which is perhaps the crown jewel of the company's pipeline, targeting what Innovus estimates is a $1Bn potential opportunity.Strong Outlook: Innovus has stated that it expects to more than triple FY15 sales in FY16, with the rise driven by a combination of growth in its commercial products and the inclusion of Beyond Human™ in results.Innovus continues to target an uplisting to a national exchange, likely the NYSE Market - a goal reiterated by management in an announcement by the company on May 17, 21016.

    Highlights of note are as follows:

    FlutiCare™ decision a significant catalyst
  6. [verwijderd] 24 mei 2016 19:28
    quote:

    Blackhamster schreef op 24 mei 2016 19:22:

    Koopjesjager waar kan ik de real time koers zien dus niet vertraagd van dit aandeel?
    Dat zou ik eerlijk gezegd niet weten. Bij mijn bank moet ik betalen voor real time USA koersen. Het zit nu rond de $0,2769 22% hoger (maar dit is ook beetje vertraagd).
  7. [verwijderd] 24 mei 2016 21:23
    Innovus Pharma Joins AbbVie Inc. and Eli Lilly & Co. in the Race for the $3 Billion Testosterone Replacement Market


    SAN DIEGO, CA--(Marketwired - May 24, 2016) - Innovus Pharmaceuticals, Inc. (OTCQB: INNV), a provider of over-the-counter and consumer products for men and women's health, vitality, and respiratory diseases, recently acquired Beyond Human for a cash purchase price of $630,000. The acquisition provided the company with natural testosterone booster supplements, including Beyond T Human® and Human Growth Agent HGA® that generated $2.2 million in revenue and $400,000 in profit last year.

    In this article, we will take a closer look at the testosterone replacement market and why the company's recent acquisition of Beyond Human is a move in the right direction.

    Testosterone Replacement

    According to the National Institutes of Health, roughly five million American men do not produce enough testosterone -- and that number is growing as the population ages. Men tend to experience a gradual decline in testosterone after the age of 30, which can cause fatigue, weakness, depression, and the loss of a sex drive. These issues can significantly decrease quality of life and have a profound impact on those in relationships.

    To view the Testosterone by Levels Age Chart please click here.

    The primary treatment for these conditions is testosterone replacement through gels or patches that must be regularly applied to maintain steady testosterone levels. More recently, implantable testosterone pellets have been released into the market as a device that is implanted under the skin of the buttocks and releases the hormone over the course of three to four months -- reducing the need for daily gels or patches.

    The global hormone replacement therapy market is expected to reach $28.4 billion in size by 2022, according to Grand View Research. Within this market, testosterone replacement is expected to grow at an ~10% compound annual growth rate, from $2.4 billion in 2013 to $3.8 billion by 2018, with most products on the market coming from large multinational companies like AbbVie Inc. (NYSE: ABBV) and Eli Lilly & Co. (NYSE: LLY), as well as from some smaller competitors.

    Alternative Approaches

    Beyond Human takes a different approach to testosterone boosting through a nutritional supplement rather than direct injection or a topical gel. The company's flagship Beyond T Human® contains Vitamin B6, Vitamin B12, Zinc, and a proprietary blend of Fenugreek, EurycomaLongifolia, RhodiolaRosea, Saw Palmetto, and Astaxanthin. Ingredients in this supplement have been published and shown to naturally boost testosterone levels without taking the hormone directly.

    Vitamin B6 suppresses the synthesis of estrogen in the body and regulates androgen production, which both help increase testosterone levels. In the short-term, vitamin B12 has been shown to raise testosterone levels dramatically after injection or ingestion. And, the herbal components of the supplement include both cordycepssinensis and tribulusterrestris, which have both been shown to improve testosterone production.

    Innovus Pharma could help further validate these claims by initiating studies to determine the efficacy of the Its BTH supplement as a whole product as it has with its Zestra® product or female sexual dysfunction, its Androferti® for male infertility and Vesele® for increasing blood flow. With its deep expertise in running clinical studies, the company's other men and women's health and vitality products have been extensively validated in the clinic in order to reassure customers that they're getting an effective treatment. Beyond T Human® also fits well within its existing sexual health product portfolio.

    Bottom Line Impact

    Beyond Human generated over $1.3 million in gross sales and approximately $300,000 in net profit during 2014, according to Innovus' press release announcing the deal. In 2015, these figures rose to $2.2 million in gross revenue and $400,000 in net profit. Management expects to grow these figures to over $3 million in gross revenue and over $600,000 in net profit once the acquisition is fully integrated into its platform over the next few years.

    Management plans to grow the newly acquired assets by selling the six new Beyond Human products through its numerous international distributors. The company also plans on leveraging Beyond Human's online platform and large database of thousands of customers to cross sell its existing products, including EjectDelay®, Sensum+®, and Vesele®. These are highly complementary products that could see strong uptake from the customer base.

    "The closing of the acquisition of the Beyond Human assets marks a turning point in Innovus Pharma revenue scale-up and we believe it should help the Company move into a cash flow positive situation followed by profitability very quickly," said Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma.

    Looking Ahead

    Innovus Pharma's acquisition of Beyond Human cements its position in the rapidly growing testosterone booster supplement industry and creates compelling synergies with its existing customers and distribution channels. Investors interested in the OTC pharmaceutical space, including companies like Aclaris Therapeutics Inc. or Teligent Inc. may want to take a closer look at the stock.

    For more information, visit the company's website at www.innovuspharma.com.

    About Innovus Pharmaceuticals, Inc.

    Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g) Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.
  8. [verwijderd] 25 mei 2016 21:03
    Tot dusver goed aandeel.

    Innovus Pharma Signs Exclusive License and Distribution Agreement With BroadMed for EjectDelay in Lebanon
    Marketwired Innovus Pharmaceuticals, Inc.
    8 hours ago
    ????
    SAN DIEGO, CA--(Marketwired - May 25, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases today announced today that it has entered into an exclusive license and distribution agreement with BroadMedSAL, a Lebanese company ("BroadMed") under which Innovus Pharma granted to BroadMed an exclusive license to market and sell Innovus product EjectDelay® indicated for treatment of premature ejaculation in Lebanon. Under the agreement, Innovus Pharma is eligible to receive up to $6.2 million in upfront and sales milestone payments plus transfer price.

    EjectDelay® is currently commercialized in the US by Innovus and in Canada under the name Uxor™ by Orimed Pharm. In addition, the Company has signed multiple commercial agreements for the product the following countries by Innovus Pharma's where the product will be registered and market by the following licensees and distributors: Elis Pharma in Turkey, Ovation Pharma in Morocco, Tabuk Pharmaceuticals for the rest of the Middle East and North Africa, OZ Biogenics in Myanmar and Vietnam.

    Bassam Damaj, President and Chief Executive Officer of Innovus Pharma, commented, "We are very happy about this latest commercial partnership collaboration with BroadMed with as this his agreement represents the sixth international commercial partnership for this product. This international partnership also represents the 11th such agreement for the Company and its products and its signing represents another milestone in the Company's execution of its international growth strategy to make our products commercially available in as many countries as possible."

    EjectDelay will be the first product to enter this market containing benzocaine. The company is expecting to sell 20,000 to 40,000 units a year in this market once approval is received from the local Ministry of Health. Approval is expected later this year.

    About EjectDelay® and Premature Ejaculation

    EjectDelay® is an over-the-counter ("OTC") U.S. Food and Drug Administration and Health Canada compliant proprietary topical treatment containing the drug benzocaine and indicated for treatment of premature ejaculation. The drug typically works within minutes of application to the glans of the penis. In clinical trials, the application of benzocaine has been shown to delay premature ejaculation by several minutes.

    Related Quotes
    INNV
    0.2720
    +4.62%
    Innovus Pharmaceuticals, Inc.? Watchlist
    0.2720+0.0120(4.62%)
    OTC Markets2:36 PM EDT

    INNOVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an EDGAR Online 8 hrs ago
    INNOVUS PHARMACEUTICALS, INC. Financials EDGAR Online Financials 4 days ago
    More
    For more information visit www.ejectdelay.com and www.uxor.ca

    Premature ejaculation ("PE") is the most common sexual dysfunction reported by men but is still under-diagnosed and under-treated. PE can happen at any age and its prevalence is consistent across all ages. In an article in The Journal of Sexual Medicine in 2007 Sex Med 2007, D.L. Patrick, D. Rowland and M. Rothman state, "Global studies consistently report that 20-30% of men experience PE worldwide. This means that PE is experienced at similar rates across the globe."

    About BroadMed Pharma

    Based in Lebanon, BroadMed is a privately held Lebanese company that markets and distributes branded generic pharmaceuticals and under-licensed products. The Company operates in 20 countries in the MENA region and has over 200 products on the market.
  9. [verwijderd] 30 mei 2016 08:04
    Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products
    Company Awaits a Potential FDA Approval for a Mega Drug
    Marketwired Innovus Pharmaceuticals Inc.
    May 11, 2016 11:03 AM
    ????
    SAN DIEGO, CA--(Marketwired - May 11, 2016) - Most micro- and small-cap biotechnology firms are development-stage opportunities with a lengthy commercialization timeline. For investors, these companies have relatively high risks due to the high costs and uncertainty of regulatory approval. Innovus Pharmaceuticals Inc. (OTCQB: INNV) is a rare exception to the rule. With 13 commercial products already on the market, the company has been generating sales from its products for two consecutive years. The company has ten signed commercial partnerships that could open the door to $500 million in potential sales milestones plus royalties in 60 countries -- a move that could make 2016 a year of record growth. In addition, the Company is awaiting approval for its FlutiCare™ OTC drug (a GlaxoSmithKline Flonase competitor) for allergic rhinitis, a market that exceeds 1 billion dollars.

    Targeting Large Markets

    Innovus Pharma operates in three major end markets that generate more than $3 billion in combined annual sales.

    The company's largest target market is allergic and non-allergic rhinitis - better known as "hay fever" or "stuffy nose" by the general public. The company's FlutiCare™ active is the #1 nasal steroid prescribed by physicians and used by patients. After dispensing more than 177 million units since 2007, Innovus is seeking to secure an Abbreviated New Drug Application from the FDA to launch an over-the-counter option for those seeking relief from rhinitis symptoms. According to a report by Fierce Pharma, GSK's Flonase OTC sold over $100,000M in a short period of time from its launch confirming the size of the market and the potential of FlutiCare™ if approved.

    Click here to watch a recent CEOLive.TV interview with Innovus Pharmaceuticals CEO Dr. Bassam Damaj.

    Female sexual dysfunction is the second market. The condition affects approximately 43% of women, compared to just 31% of men reporting similar difficulties. Whereas erectile dysfunction has become a $6 billion market, INNV's Zestra® is the only clinically proven, commercially sold consumer care product with statistical significance in addressing these issues for women. The company has sold more than 12.5 million doses sold to date.

    Click here to view Zestra® Study Results

    Premature ejaculation, Innovus' third target area, affects nearly a third of men with few solutions on the market that effectively address the problem. The company's EjectDelay® over-the-counter gel has demonstrated improved intra-vaginal ejaculation latency time by 6.4 minutes compared to placebo treatments. Notably, this is significantly better than other drugs on the market, including Dapoxetine and Tempe, which have less than a five-minute improvement.

    Click here to view EjectDelay Study Results

    Expanding Revenue Potential

    Related Quotes
    INNV
    0.2037
    -10.26%
    Innovus Pharmaceuticals, Inc.? Watchlist
    0.2037-0.0233(10.26%)
    OTC MarketsFri, May 27, 2016 3:59 PM EDT

    INNOVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an EDGAR Online 4 days ago
    INNOVUS PHARMACEUTICALS, INC. Financials EDGAR Online Financials 8 days ago
    More
    Innovus Pharma has significantly expanded its revenue potential moving into 2016 after signing new distribution deals and making a strategic acquisition.

    As of early 2016, the company signed a total of ten commercial partnership deals with over $500 million in potential sales milestones plus royalties in 60 countries. The company already has significant distribution in the United States through Walmart, Target, Walgreen's Drugstore.com, and numerous other retailers, but these new distribution agreements will help expand international sales and develop a key pathway for future revenue growth.

    The company also acquired Beyond Human assets in March of 2016, which had revenues of $1.3 million in 2013 and $2.2 million in 2014. With the new acquisition under its belt, the company adds a natural Testosterone booster and a natural Human Growth Agent to its product portfolio. The acquisition should also be accretive over the near-term since the private company generated some $400,000 in net profits in 2015 - up from $300,000 the year prior.

    Finally, the company has been actively expanding the potential of its existing products by moving them from prescription products into the mass market. These efforts could significantly expand its overall market and improve revenues over the long-term. Management also plans to launch these OTC products into international markets in order to further expand sales.

    Improving Financial Condition

    Innovus Pharma recently raised $2.5 million in growth capital and repaid all of its outstanding debt, which puts the company on solid financial footing. In 2016, the company plans to become cash flow positive, and in 2017, it plans to become profitable on its income statement. These developments could set the stage for significant shareholder value creation as the company generates cash that can be reinvested in growth or distributed to shareholders.

    In order to expand liquidity, the company plans to up-list to the NYSE MKT by the end of the year. The move could open the door to greater institutional investment, since many mutual funds and other institutions are forbidden from investing in stocks trading over-the-counter.

    On April 19, SeeThruEquity issued a buy rating and $0.80 per share price target on the company. The analyst firm views the company as a high risk, high reward investment opportunity in the OTC pharmaceuticals space with a differentiated business model focused on men and women's health and vitality, and an expanding international presence. With a current share price of less than $0.10, the price target reflects a potential 8x profit.

    Potential Catalysts Ahead

    Innovus Pharma has numerous upcoming catalysts that may warrant a closer look by potential investors. With its new agreements in place, the company could see significant sales expansion throughout 2016 and into 2017. An up-listing to the NYSE MKT could expand its investor reach at the same time and build liquidity into the stock. At least one analyst believes that this could lead to a significant increase in share price over the next year.

    Investors in the over-the-counter pharmaceutical or generics space, including small-cap companies like Juniper Pharmaceuticals Inc., Aclaris Therapeutics Inc., or Teligent Inc., may want to take a closer look at the stock.
  11. [verwijderd] 1 juni 2016 19:04
    Innovus (INNV) Brings Leading Nasal Steroid From Rx to OTC
    Marketwired Innovus Pharmaceuticals Inc.
    7 hours ago

    SAN DIEGO, CA--(Marketwired - Jun 1, 2016) - Innovus Pharmaceuticals Inc. (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative, and effective over-the-counter medicine and consumer care products, plans to launch a new product into a multi-billion dollar market in the near-term. After acquiring over-the-counter rights to FlutiCare™ -- a leading prescription nasal steroid -- in February 2015, the company expects to receive regulatory approval later this year.

    In this article, we will take a look at the company's plans to transition FlutiCare™ from a prescription nasal steroid into an over-the-counter treatment, as well as the timeline to launch and the financial potential from the move over the coming years.

    Rx to OTC Transition

    FlutiCare™ is the leading nasal steroid recommended by physicians for the treatment of nasal congestion, sneezing, runny nose, and itchy nose. While GlaxoSmithKline's Rx Flonase brand has sold roughly two million units, FlutiCare™ Rx form has sold more than 177 million units, making it a clear leader in the Rx nasal steroid market. Both of these products will compete against Sanofi's Nasacort, which has been the only product on the market for a year.

    In addition to competing with each other, nasal steroids compete with OTC allergy products that alleviate many of the same symptoms, including so-called "D" allergy pills like Bayer's Claritin and Johnson & Johnson's Zyrtec. While these products are popular among allergy sufferers, they aren't as effective as many Rx nasal steroids at clearing nasal-specific symptoms associated with allergies, such as a runny or stuffy nose.

    The nasal steroid market is expected to become a $1+ billion market opportunity as these brands transition from prescription-only to over-the-counter. With 75% market share in the prescription market, FlutiCare™ is well positioned to become a clear leader in the OTC market given its efficacy and patient satisfaction if approved by the FDA. The company will initially target these existing Rx users and expand the market to include external customers over the coming years.

    Related Quotes
    INNV
    0.1990
    +7.51%
    Innovus Pharmaceuticals, Inc.? Watchlist
    0.1990+0.0139(7.51%)
    OTC Markets12:46 PM EDT

    INNOVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an EDGAR Online 7 days ago
    INNOVUS PHARMACEUTICALS, INC. Financials EDGAR Online Financials 10 days ago
    More
    Time to Market

    The over-the-counter Abbreviated New Drug Application (ANDA) for the product was filed with the U.S. Food & Drug Administration during the fourth quarter of 2014. In January of 2015, the FDA accepted the ANDA for review and the application has been making its way through the lengthy approval process. The good news is that ANDA applications take less time than NDA applications, since the drug already has been approved in prescription form.

    According to an April 2016 investor presentation, the company anticipates approval of the new OTC ANDA during summer 2016. Should the company receive approval on the product at this time, management plans to launch the product during late Q4 2016 or early Q1 of 2017 through a variety of different channels.

    It is worth noting that the FDA's approval of the ANDA could be a significant catalyst for the stock in the near-term. The commercialization of FlutiCare™ is a significant long-term catalyst for the stock as revenues accelerate. The unique combination of a short- and long-term catalyst might make the stock appealing to investors.

    Marketing Strategy

    Innovus plans to launch the over-the-counter version of FlutiCare™ through both traditional retailers, such as Target, Walgreens's Drugstore, and CVS where it already has a presence in the OTC space, as well as through online channels. As the #1 nasal steroid used by Rx patients and the #1 nasal steroid prescribed by physicians, the company is well positioned to capitalize on the market opportunity and unlock significant long-term value for shareholders.

    The company plans to launch a media campaign when the OTC indication is approved that will include television, sponsored field surveys, and print advertising among other channels. In addition, the company will market directly to healthcare professionals and pharmacists to encourage referrals for the product. And finally, the company has developed attractive in-store advertising to target consumers at the point of purchase.

    FlutiCare™ is also ideally suited for online distribution given its potential for customer loyalty and relatively high per unit retail value that provides margin cushion. The company plans on using the FlutiCare™ brand website as a content marketing hub for allergic rhinitis sufferers, while leveraging a dynamic e-mail platform and detailed analytics to ensure a high return on investment for its marketing efforts and enable real-time improvements.

  13. [verwijderd] 14 juli 2016 16:00
    fluticare approval van de FDA komt wrs nu binnen 3 weken. Aandeel loopt alvast warm.

    Miss is dit wel het enigste bedrijf op de hele otc wat geen scam is en goede omzet draait.

    nu 16% erbij en gister iets van 25% erbij. Gaat op zeer korte termijn naar $0,40. En bij approval richting de $1
19 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 860,01 -0,62%
EUR/USD 1,0652 +0,08%
FTSE 100 7.895,85 +0,24%
Germany40^ 17.717,40 -0,67%
Gold spot 2.393,06 +0,58%
NY-Nasdaq Composite 15.601,50 -0,52%

Stijgers

WDP
+3,12%
Kendrion
+2,92%
EBUSCO...
+2,67%
Vopak
+2,61%
NX FIL...
+2,17%

Dalers

JUST E...
-5,11%
TomTom
-4,68%
Fugro
-4,30%
ASMI
-4,00%
BESI
-3,64%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!